The discovery of the JAK2 and MPL mutations has been of enormous help in the diagnosis and characterization of chronic myeloproliferative disorders, and has opened new perspectives for targeted therapy. In this perspective article, Drs. Vannucchi and Guglielmelli review additional molecular mechanisms that may contribute to the pathogenesis of these disorders, such as aberrant expression of microRNA. See related papers on pages 1009 and 1098.
No takes yet. Share an insight, caveat, or question.
Vannucchi et al. (2008) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: